Homocysteine (Hcy) is the immediate precursor of the amino acid, methionine. In humans, blood concentrations of Hcy may become elevated as a result of deficiency in folate, vitamin B6 or vitamin B12 and has recently been identified as a putative risk factor for a number of age-associated disease states including arteriosclerosis, myocardial infarction, arterial occlusive disease, Alzheimer's disease and neural tube defects. A specific role for Hcy or any of its metabolites, such as S-adenosyl Hcy (SAH) or Hcy thiolactone, in these conditions has not yet been firmly established. Particularly absent is a description of the effects of elevated Hcy levels on immune function. Several studies have examined the effects of Hcy on monocyte, neutrophil and B cell function, inflammation and chemokine production; however, little is known about the Hcy effects on T lymphocytes. Our initial studies revealed that treatment of resting human T cells with Hcy (100-1000 micromolar) resulted in a dose-dependent increase in apoptotic cell death. D, L Hcy was more potent than Hcy thiolactone in this respect while SAH was found to be significantly less active or inactive in many cases. We also found that the pro-apoptotic effects of Hcy were abrogated with the addition of serum, pan-caspase inhibitors, and poly-ADP-ribose polymerase (PARP) inhibitors to the cell cultures. These results suggest that D,L-Hcy, like other apoptotic stressors, leads to the activation of the caspase cascade and eventually to the cleavage of the key cellular proteins, like PARP, eventually leading to the typical morphological changes observed in cells undergoing apoptosis. We have also found that Hcy-mediated apoptosis is inhibited by the phosphatase inhibitor, sodium orthovanadate, the intracellular calcium chelator, BAPTA-AM, and the protein synthesis inhibitor, cycloheximide. Moreover, we have also found that Hcy appears to potentiate cellular death induced by a number of other established apoptotic signals including activation-induced cell death (AICD), heat shock, and Fas ligand- and HIV-mediated T cell death. In addition to the pro-apoptotic effects of Hcy, stimulation of mononuclear cells or isolated T cells with immobilized anti-CD3 mAb in the presence of Hcy or thiolactone but not SAH resulted in a significant increase in several type 1 cytokines including IL-2, IFN-gamma, TNF-alpha and IL-10 but not the type 2 cytokines, IL-4 or IL-5. More detailed examination of the Hcy effects on T cell activation revealed that this type 1 cytokine production profile is mediated, in part, through the production of IL-18 and possibly IL-12. The precise mechanism involved in the generation of these cytokines is currently under investigation but we believe the Hcy effect is being mediated, in part, by specific stress-associated signals post Hcy treatment. Overall, Hcy appears to exert a number of differential effects on immune cells, which may alter immune function in the circulation and tissue microenvironment with age and disease pathology. A greater understanding of the potential modulatory effects of Hcy and its metabolites on immune function may result in the development of potential therapeutic strategies to control and optimize immune responses with age, AIDS and in various age-associated disease states.

National Institute of Health (NIH)
National Institute on Aging (NIA)
Intramural Research (Z01)
Project #
Application #
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
United States
Zip Code